Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
03 janv. 2017 16h52 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in...